Barry, OppHub America Desk · · Source: prnewswire-all
Capricor Therapeutics Investors Urged to Act in Securities Fraud Lawsuit
Based on reporting from prnewswire-all.
Capricor Therapeutics (NASDAQ: CAPR) faces a securities fraud lawsuit concerning its Deramiocel BLA resubmission. Investors who purchased shares between December 17, 2025, and July 26, 2026, have until September 28, 2026, to act. The lawsuit alleges misleading statements regarding the FDA submission process.
Market context for this story
As of: After HoursLoading quotes…
Informational only — not investment advice. Full markets →
Related markets
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).
Capricor Therapeutics·$CAPR$CAPRCapricor Therapeutics
TradingView
Live chart & market data via TradingView · Delayed or exchange real-time per TradingView data agreements · Not investment advice
Educational TradingView chart — search any symbol in the widget. Confirm on /markets/CAPR. Not investment advice.
## Catalyst Analysis: Securities Fraud Lawsuit
Schall, Brown & Schwartz LLP, a national shareholder rights litigation firm, is notifying investors of a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: $CAPR+WL). The suit alleges violations of securities laws related to the company's Biologics License Application (BLA) for Deramiocel.
## Technical Analysis & Key Risk Watch
Key levels for (educational): R2 $229.67 · R1 $214.19 · last $205.81 · S1 $205.43 · S2 ## Technical Analysis & Key Risk Watch 84.88.
The class period for affected investors spans from December 17, 2025, to July 26, 2026. The deadline for shareholders to participate or seek lead plaintiff status is September 28, 2026. The complaint asserts that Capricor altered its statistical analysis plan for clinical data without FDA agreement before resubmitting its BLA, potentially leading to regulatory rejection due to insufficient effectiveness evidence.
## Impact on Capricor Therapeutics ($CAPR+WL)
Investors who suffered losses during the specified class period are encouraged to contact Schall, Brown & Schwartz LLP to discuss their rights. The firm highlights that appointment as lead plaintiff is not a prerequisite for participating in any potential recovery. Shareholders can remain absent class members if they choose to take no action.
Read the full story
Original reporting and related coverage — attribution links only, not paid recommendations.
Trade this story
Robinhood
Webull
Tradier
IBKR
Chart this story
TradingView
Broker and exchange buttons use invite / refer-a-friend links (rewards may be capped). Charting links (TradingView) are partner offers that may pay OppHub America a commission at no extra cost to you.
OppSHOP
Full OppSHOP →As an Amazon Associate, OppHub America earns from qualifying purchases. Shopping here helps keep the site free — at no extra cost to you. Disclosure
Story playbook
A pre-built map of what to watch — stocks, ETFs, and educational next steps. Not personalized advice.
Snapshot date: August 3, 2026 at 1:06 AM ET
This playbook was built when the story published and is not live-updated. Prices, news, and risk can change after this date — treat it as a starting map, not a current trade ticket.
Story → money map
biotech litigation
Capricor Therapeutics is being sued by investors who claim the company misled them about a drug approval process with the government. People who lost money on this stock have a deadline in September 2026 to join the legal action.
What changed
A securities fraud class action lawsuit was filed against Capricor Therapeutics over its regulatory submission process.
Who wins / who loses
Plaintiff law firms and short-term traders benefit from volatility or legal recovery, while long-term shareholders of Capricor face regulatory uncertainty and legal headwinds.
Time horizon
Think in terms of the next few weeks.
Confidence & best fit
high confidence · Active trader
Safer theme exposure (ETFs)
Baskets that own the theme without betting on one company.
Single stocks (higher risk)
Primary = closest to the story · Peers = same industry · Second-order = knock-on effects · Avoid = looks related but may be a trap
Primary
- $CAPRStay away — for now
The company whose stock is in trouble due to a major lawsuit, making it risky to buy right now.
View $CAPR chart → · End-of-day delayed data
Options (education only)
No strikes or expiries — a framework for how traders might express the view. Options can expire worthless.
Direction: bearish · Style: Protective put / downside hedge idea · Level: intermediate
Beginners should skip options here because sudden legal and drug-approval news can make the stock move unpredictably.
Income / OppHub America angle
Not a trade tip — ways to use the insight outside the market.
- Monitor shareholder rights law firm announcements for potential class action recovery eligibility.
What would break this thesis
- FDA grants rapid approval or positive clinical data resolution clears the legal overhang.
What to do next on OppHub America
Saved playbooks stay on this device for now.
Important
Not financial advice. OppHub America playbooks are educational market maps only — not recommendations to buy, sell, or hold any security. Markets move fast; information can be wrong or outdated. Trade and invest at your own risk. Do your own research or consult a licensed advisor.
Based on reporting from prnewswire-all.
Informational and educational only — not investment, financial, or legal advice. Disclosure
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).